RADAR on Specialty Pharmacy

Multiple Oncology Biosimilars Could Prompt Preferencing

An earlier version of this story incorrectly said that Neupogen (filgrastim) and Neulasta (pegfilgrastim) are Pfizer Inc. treatments. They are Amgen Inc. products. This version has been corrected. So far, biosim...

HHS Importation Efforts Move Ahead, but Questions Remain

Late last month, the Trump administration moved ahead with a proposed rule and draft guidance that could open the door to drug importation. The moves, it contended, would lower U.S. prescription drug prices. But ske...

Novel New Drugs, 10 Biosimilar Approvals Were 2019 Standouts

While arguably the biggest news within the specialty pharmacy arena in 2019 was the U.S. approval and launch of the $2.1 million gene therapy Zolgensma (onasemnogene abeparvovec-xioi) (RSP 6/19, p. 1), plenty of oth...

Troubles for Industry Veteran Diplomat Began Few Years Ago

Diplomat Pharmacy, Inc.’s sale to OptumRx (see story, p. 1) will mark the end of a specialty pharmacy that is nearly half a century old. Diplomat began operations in 1975 as a small, regional operation, and, in...

New FDA Specialty Approvals

✦ Dec. 3: The FDA expanded the label of Tecentriq (atezolizumab) in combination with Abraxane (paclitaxel protein-bound) and carboplatin for the first-line treatment of adults with metastatic non-squamous non-smal...

News Briefs

✦ Express Scripts and Prime Therapeutics LLC unveiled a partnership by which the former will offer the latter services related to retail pharmacy network and drug manufacturer contracts. Through the three-year dea...